Sponsored by:
Hewlett Packard (HPQ)
Dell (DELL)
Facebook (FB)
Apple (AAPL)
Focus Stocks
Featured Stories
Fred's First Quarter 2012 EPS Increase 17%
Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook
Best ETFs For Facebook Exposure
McDonald's Announces Quarterly Cash Dividend
Is KB HOME Closing in to Resistance?
Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
Published on Tuesday, 07 February 2012 16:21 Written by TradersHuddle Staff
CARLSBAD, Calif., Feb. 7, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for the quarter and full year ended December 31, 2011 and provided financial guidance for 2012.
(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)
"I am pleased with our performance in the fourth quarter and throughout 2011, even as we faced a number of challenges, including macroeconomic headwinds and constrained spending by some of our customers," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "Overcoming these obstacles, we delivered top line growth, reduced our operating costs to meet the slower growth environment and expanded our operating margins an impressive 110 basis points, all of which we leveraged to deliver bottom line growth for the twelfth consecutive year. We finished the year with strong free cash flow of $710 million."
"Looking ahead to 2012, we expect growth in our game-changing Ion Torrent franchise, expansion in end markets and geographies and continued operational efficiencies to drive organic revenue growth of 2 to 4 percent over 2011 results and adjusted non-GAAP EPS in a range of $3.90 to $4.05."
Life Technologies reported results compared to quarter and year ended December 31, 2010.
Analysis of Fourth Quarter 2011 and Fiscal Year 2011 Results
- Fourth quarter non-GAAP 2011 revenue increased 4 percent, or 3 percent excluding the impact from currency, with particularly strong growth in sales of Ion Torrent and Forensics. Full year non-GAAP 2011 revenue increased 4 percent, or 3 percent excluding the impact from currency, driven by increased sales of Ion Torrent, BioProduction and Forensics. The increase in both periods was partially offset by a decrease in sales of SOLiD products.
- Non-GAAP gross margin in the fourth quarter increased 20 basis points to 64.8 percent, driven primarily by realized price and increased manufacturing productivity, which were partially offset by product mix and the termination of a supply agreement. Full year non-GAAP gross margin was 65.3 percent, a decrease of 150 basis points, due to currency hedging losses, upgrades to our SOLiD 5500 and Ion Torrent sales, which were partially offset by realized price and manufacturing productivity.
- Non-GAAP operating margin increased 470 basis points to 31 percent in the fourth quarter, representing an all time high for the Company. Full year operating margin increased 40 basis points to 29.1 percent and, excluding currency, expanded 110 basis points. The increase in both periods resulted from a reduction in operating expenses including cost savings initiatives, a portion of which was offset by expenses related to developing Ion Torrent.
- The non-GAAP tax rate was 26.8 percent for the fourth quarter and 27.3 percent for the full year.
- Fourth quarter non-GAAP EPS increased 18 percent to $1.06. Full year non-GAAP EPS increased 5 percent to $3.73.
- Diluted weighted shares outstanding were 184.5 million in the fourth quarter.
- Cash flow from operating activities for the fourth quarter was $316 million. Fourth quarter capital expenditures were $34 million and resulting free cash flow was $282 million. The company ended the quarter with $882 million in cash and short-term investments.
Business Highlights:
- Genetic Systems division non-GAAP revenue increased 13 percent to $278 million in the fourth quarter, or 11 percent excluding the impact from currency. Growth in the current year quarter was driven by increased sales of Ion Torrent and double digit growth in Forensics, which was partially offset by reduced sales of SOLiD products. Full year non-GAAP revenue increased 8 percent to $1 billion, or 7 percent excluding the impact from currency. Growth for the full year period was driven by increased sales of Ion Torrent franchise, growth in Forensics and Capillary Electrophoresis, all of which was partially offset by lower growth in SOLiD products.
- Molecular Biology Systems division non-GAAP revenue decreased 1 percent to $441 million in the fourth quarter, or 2 percent excluding the impact of currency. The decline in the current year quarter resulted from a decline in qPCR royalties and continued lower spending by academic customers. Full year non-GAAP revenue was $1.7 billion, flat compared to the prior year period, and decreased 2 percent excluding the impact of currency. The decrease for the full year was the result of lower qPCR royalties, slower funding which drove lower PCR sales and a disruption in China sales as the company transitioned certain dealer networks to direct sales during the second quarter of 2011.
- Cell Systems division non-GAAP revenue increased 3 percent to $244 million in the fourth quarter, or 1 percent excluding the impact of currency, compared to a strong fourth quarter of 2010. Growth in the fourth quarter was driven by increased sales of cell culture products and by increased sales in BioProduction. Full year non-GAAP revenue increased 7 percent to $969 million, or 6 percent excluding the impact of currency. Full year growth was driven by increased BioProduction sales and sales across our cell consumables businesses.
- Regional organic growth rates for the quarter were as follows: the Americas was flat, Europe grew 4 percent, Asia Pacific grew 10 percent and Japan grew 4 percent. Full year growth rates were as follows: the Americas was 2%, Europe grew 3 percent, Asia Pacific 9 percent, and Japan declined 3 percent.
- Revenue from orders transacted through Life Technologies' eCommerce channels grew approximately 8 percent during the quarter and approximately 12 percent for the full year. Over 50 percent of all transactions globally are processed using eCommerce platforms.
Changes in Reporting
The company plans to modify its reporting to better align with changes it has made in its internal organization. These changes have no impact on results of operations, financial condition or cash flows of the Company as a whole.
The company currently reports revenues for three divisions: Molecular Biology Systems, Genetic Systems and Cell Systems. Starting in the first quarter of 2012, the company will report revenues for the following three business groups: Research Consumables, Genetic Analysis and Applied Sciences. These changes will be finalized during and effective for the first quarter of 2012 and the company will provide revised financial data reflecting these changes prior to reporting its first quarter results in April 2012.
Fiscal Year 2012 Outlook
Subject to the risk factors detailed in the Safe Harbor Statement section of this release, the company provided its expectations for fiscal year 2012 financial performance. The company expects organic revenue growth of 2 to 4 percent over 2011 revenues of $3.7 billion and non-GAAP earnings per share to be in a range of $3.90 to $4.05. The guidance includes a revenue headwind of approximately $26 million, or 0.7 percent, and a benefit to non-GAAP EPS of approximately $0.02 from currency. The currency impact consists of a negative effect from changes in currency exchange rates based on December 2011 month end rates, partially offset by a benefit from not having the hedge losses that occurred in 2011. The company will provide further detail on its business outlook during the webcast today.
Webcast Details
The company will discuss its financial and business results as well as its business outlook on its webcast at 4:30 PM ET today. This webcast will contain forward-looking information. The webcast will include a discussion of "non-GAAP financial measures" as that term is defined in Regulation G. For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial measures to the company's financial results determined in accordance with GAAP, as well as other material financial and statistical information to be discussed on the webcast will be posted at the company's Investor Relations Web site at https://ir.lifetechnologies.com. The webcast can be accessed through the investor relations page of the Life Technologies' website at https://ir.lifetechnologies.com/events.cfm. A replay of the webcast will be available on the company's website through Tuesday, February 28, 2012.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.7 billion in 2011, employs approximately 10,400 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.
Safe Harbor Statement
Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intend that such forward-looking statements be subject to the safe harbor created thereby. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of the company. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; and corporate strategy and performance. A number of the matters discussed in this press release and presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC. This press release and presentation speaks only as of its date, and the company disclaims any duty to update the information herein.
Non-GAAP Measurements
This press release includes certain financial information which constitutes "non-GAAP financial measures" as defined by the SEC. The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most directly comparable GAAP measures, can be found at on the Investor Relations portion of the company's website at www.lifetechnologies.com.
Investor and Financial Contact:
Carol Cox
Investor Relations
(760) 603-7208
This e-mail address is being protected from spambots. You need JavaScript enabled to view it.
LIFE TECHNOLOGIES CORPORATION | |||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
AND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1) | |||||||||||||
For the three months | For the three months | ||||||||||||
(in thousands, except per share data) | ended December 31, 2011 | ended December 31, 2010 | |||||||||||
(unaudited) | |||||||||||||
GAAP | Adjustments | Non-GAAP | GAAP | Adjustments | Non-GAAP | ||||||||
Revenues | $ 1,010,445 | $ (40,106) | (2) | $ 970,339 | $ 932,337 | $ 1,301 | (2) | $ 933,638 | |||||
Cost of revenues | 345,305 | (3,855) | (3) | $ 341,450 | 330,940 | (104) | (3) | 330,836 | |||||
Purchased intangibles amortization | 82,201 | (82,201) | (4) | - | 83,401 | (83,401) | (4) | - | |||||
Gross profit | 582,939 | 45,950 | 628,889 | 517,996 | 84,806 | 602,802 | |||||||
Gross margin | 57.7% | 64.8% | 55.6% | 64.6% | |||||||||
Operating expenses: | |||||||||||||
Selling, general and administrative | 249,535 | (5,864) | (5) | 243,671 | 270,001 | (11,200) | (5) | 258,801 | |||||
Research and development | 90,201 | (5,587) | (5) | 84,614 | 108,711 | (10,119) | (5) | 98,592 | |||||
Business consolidation costs | 18,856 | (18,856) | (6) | - | 27,025 | (27,025) | (6) | - | |||||
Total operating expenses | 358,592 | (30,307) | 328,285 | 405,737 | (48,344) | 357,393 | |||||||
Operating income | 224,347 | 76,257 | 300,604 | 112,259 | 133,150 | 245,409 | |||||||
Operating margin | 22.2% | 31.0% | 12.0% | 26.3% | |||||||||
Interest income | 972 | 972 | 678 | 678 | |||||||||
Interest expense | (38,162) | 6,649 | (7) | (31,513) | (36,289) | 8,617 | (7) | (27,672) | |||||
Other income (expense), net | (2,933) | - | (2,933) | 385 | (559) | (8) | (174) | ||||||
Total other income (expense), net | (40,123) | 6,649 | (33,474) | (35,226) | 8,058 | (27,168) | |||||||
Income from operations before provision for | |||||||||||||
income taxes | 184,224 | 82,906 | 267,130 | 77,033 | 141,208 | 218,241 | |||||||
Income tax provision | (56,871) | (14,814) | (9) | (71,685) | (6,465) | (39,466) | (9) | (45,931) | |||||
Net income | 127,353 | 68,092 | 195,445 | 70,568 | 101,742 | 172,310 | |||||||
Net loss attributable to non-controlling interests | - | - | - | 113 | (98) | (10) | 15 | ||||||
Net income attributable to controlling interest | $ 127,353 | $ 68,092 | $ 195,445 | $ 70,681 | $ 101,644 | $ 172,325 | |||||||
Effective tax rate | 30.9% | 26.8% | 8.4% | 21.0% | |||||||||
Add back interest expense for subordinated | |||||||||||||
debt, net of tax | 584 | (551) | (11) | 33 | - | - | |||||||
Numerator for diluted earnings | |||||||||||||
per share | $ 127,937 | $ 67,541 | $ 195,478 | $ 70,681 | $ 101,644 | $ 172,325 | |||||||
Earnings per common share: | |||||||||||||
Basic earnings per share attributable to controlling interest | $ 0.71 | $ 1.10 | $ 0.38 | $ 0.93 | |||||||||
Diluted earnings per share attributable to controlling interest | $ 0.69 | $ 1.06 | $ 0.37 | $ 0.90 | |||||||||
Weighted average shares used in per share calculation: | |||||||||||||
Basic | 178,304 | 178,304 | 186,046 | 186,046 | |||||||||
Diluted | 184,544 | 184,544 | 191,227 | 191,227 | |||||||||
(1) | The Company reports Non-GAAP results which exclude costs that are not indicative of the profitability or cash flows of the Company’s ongoing or future operations. Such costs include restructuring charges, business transformation expenses, amortization and depreciation of deferred revenue, intangibles assets, and fixed assets, revaluation charges for inventories, contingent consideration liabilities, and asset impairments, and in process research and development expenses incurred as a result of business combinations, as well as the impact from the divestiture and discontinuance of product lines. The Company also excludes noncash interest expense associated with convertible debt bifurcation and noncash charges associated with non-controlling interests. In addition, the Company excludes one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations. | ||
(2) | Adjust for royalty revenue recognized upon a historical and current licensing settlement of $38.8 million and revenue related to credit usage on returns of a discontinued product of $1.8 million, offset with fair value amortization of purchased deferred revenue of $0.5 million for the three months ended December 31, 2011. Add back fair value amortization of purchased deferred revenue of $1.3 million for the three months ended December 31, 2010. | ||
(3) | Add back royalty fees and expenses of $4.5 million related to the historical portion of the settlement of a licensing dispute, offset with contingent consideration revaluation of $0.6 million for the three months ended December 31, 2011. Add back noncash charges for purchase accounting inventory revaluations cost of $0.1 million for the three months ended December 31, 2010. | ||
(4) | Add back amortization of purchased intangibles. | ||
(5) | Add back $10.0 million for expenses and an asset impairment partially offset by recovery of expenses related to the historical portion of the settlement of a licensing dispute and depreciation of purchase accounting property, plant, and equipment revaluations of $1.5 million for the three months ended December 31, 2011. Add back depreciation of purchase accounting property, plant, and equipment revaluations of $2.4 million and accelerated compensation expenses related to business acquisitions of $18.9 million for the three months ended December 31, 2010. | ||
(6) | Add back business consolidation costs. | ||
(7) | Add back charges related to noncash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $5.1 million and $7.1 million for the three months ended December 31, 2011 and 2010, respectively. Adjust for imputed finance charges of $1.5 million associated with contingent consideration on business acquisitions for each of the three months ended December 31, 2011 and 2010. | ||
(8) | Adjust for a discontinuance gain recognized on cash flow hedge of $0.6 million for the three months ended December 31, 2010. | ||
(9) | Non-GAAP tax differs from GAAP tax expense due to the exclusion of the aforementioned business combination related charges, non cash charges, and one-time costs which are not indicative of the profitability or cash flows of the Company’s ongoing or future operations. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation. | ||
(10) | Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant, and equipment revaluations attributable to non-controlling interest, net of tax benefit. | ||
(11) | Eliminate noncash interest charges from diluted earnings per share calculation, as the noncash interest is excluded from the calculation of Non-GAAP net income. | ||
LIFE TECHNOLOGIES CORPORATION | |||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
AND RECONCILIATION OF NON-GAAP ADJUSTMENTS(1) | |||||||||||||
For the year ended | For the year ended | ||||||||||||
(in thousands, except per share data) | December 31, 2011 | December 31, 2010 | |||||||||||
(unaudited) | |||||||||||||
GAAP | Adjustments | Non-GAAP | GAAP | Adjustments | Non-GAAP | ||||||||
Revenues | $ 3,775,672 | $ (34,995) | (2) | $ 3,740,677 | $ 3,588,094 | $ 6,746 | (2) | $ 3,594,840 | |||||
Cost of revenues | 1,301,145 | (4,394) | (3) | $ 1,296,751 | 1,188,199 | 5,360 | (3) | 1,193,559 | |||||
Purchased intangibles amortization | 308,728 | (308,728) | (4) | - | 293,754 | (293,754) | (4) | - | |||||
Gross profit | 2,165,799 | 278,127 | 2,443,926 | 2,106,141 | 295,140 | 2,401,281 | |||||||
Gross margin | 57.4% | 65.3% | 58.7% | 66.8% | |||||||||
Operating expenses: | |||||||||||||
Selling, general and administrative | 1,008,973 | (10,776) | (5) | 998,197 | 1,023,179 | (17,096) | (5) | 1,006,083 | |||||
Research and development | 377,924 | (21,561) | (5) | 356,363 | 375,465 | (12,208) | (5) | 363,257 | |||||
Purchased in-process research and development | - | - | - | 1,650 | (1,650) | (4) | - | ||||||
Business consolidation costs | 75,324 | (75,324) | (6) | - | 93,450 | (93,450) | (6) | - | |||||
Total operating expenses | 1,462,221 | (107,661) | 1,354,560 | 1,493,744 | (124,404) | 1,369,340 | |||||||
Operating income | 703,578 | 385,788 | 1,089,366 | 612,397 | 419,544 | 1,031,941 | |||||||
Operating margin | 18.6% | 29.1% | 17.1% | 28.7% | |||||||||
Interest income | 3,932 | - | 3,932 | 4,266 | - | 4,266 | |||||||
Interest expense | (162,073) | 30,779 | (7) | (131,294) | (152,322) | 39,582 | (7) | (112,740) | |||||
Loss on early retirement of debt | - | - | - | (54,185) | 54,185 | (8) | - | ||||||
Gain on divestiture of equity investments | - | - | - | 37,260 | (37,260) | (9) | - | ||||||
Other income (expense), net | (10,913) | - | (10,913) | (5,864) | 5,500 | (10) | (364) | ||||||
Total other income (expense), net | (169,054) | 30,779 | (138,275) | (170,845) | 62,007 | (108,838) | |||||||
Income from operations before provision for | |||||||||||||
income taxes | 534,524 | 416,567 | 951,091 | 441,552 | 481,551 | 923,103 | |||||||
Income tax provision | (122,405) | (137,424) | (11) | (259,829) | (63,694) | (182,994) | (11) | (246,688) | |||||
Net income | 412,119 | 279,143 | 691,262 | 377,858 | 298,557 | 676,415 | |||||||
Net loss attributable to non-controlling interests | 658 | (308) | (12) | 350 | 437 | (290) | (12) | 147 | |||||
Net income attributable to controlling interest | $ 412,777 | $ 278,835 | $ 691,612 | $ 378,295 | $ 298,267 | $ 676,562 | |||||||
Effective tax rate | 22.9% | 27.3% | 14.4% | 26.7% | |||||||||
Add back interest expense for subordinated | |||||||||||||
debt, net of tax | 1,300 | (1,169) | (13) | 131 | 171 | 171 | |||||||
Numerator for diluted earnings | |||||||||||||
per share | $ 414,077 | $ 277,666 | $ 691,743 | $ 378,466 | $ 298,267 | $ 676,733 | |||||||
Earnings per common share: | |||||||||||||
Basic earnings per share attributable to controlling interest | $ 2.30 | $ 3.86 | $ 2.06 | $ 3.69 | |||||||||
Diluted earnings per share attributable to controlling interest | $ 2.23 | $ 3.73 | $ 1.99 | $ 3.55 | |||||||||
Weighted average shares used in per share calculation: | |||||||||||||
Basic | 179,390 | 179,390 | 183,398 | 183,398 | |||||||||
Diluted | 185,595 | 185,595 | 190,591 | 190,591 | |||||||||
(1) | The Company reports Non-GAAP results which excludes costs that are not indicative of the profitability or cash flows of the Company’s ongoing or future operations. Such costs are restructuring cost, business transformation expenses, amortization and depreciation of deferred revenue, intangibles assets, and fixed assets, and revaluation charges for inventories, contingent consideration liabilities, asset impairments, and in process research and development expenses, incurred as a result of business combinations as well as the impact from the divestiture and discontinuance of product lines. The Company also excludes noncash interest expense associated with convertible debt bifurcation and noncash charges associated with non-controlling interests. In addition, the Company excludes one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations. | ||
(2) | Adjust for royalty revenue recognized upon a historical and current licensing settlement of $38.8 million, offset with fair value amortization of purchased deferred revenue of $2.9 million and add back revenue related to returns of a discontinued product of $0.9 million for the year ended December 31, 2011. Add back fair value amortization of purchased deferred revenue of $6.7 million for the year ended December 31, 2010. | ||
(3) | Add back royalty fees and expenses of $4.5 million related to the historical portion of the settlement of a licensing dispute, charges for inventory reserves related to a discontinued product of $2.1 million, and $0.5 million of purchase accounting related cost of revenue revaluation, offset by contingent consideration revaluation of $2.7 million for the year ended December 31, 2011. Add back noncash charges for purchase accounting inventory revaluation cost of $0.9 million, offset with contingent consideration revaluation of $6.3 million for the year ended December 31, 2010. | ||
(4) | Add back amortization of purchased intangibles and write off of purchased in-process research and development. | ||
(5) | Add back contingent consideration revaluation of $13.7 million, depreciation of purchase accounting property, plant, and equipment revaluations of $7.1 million, $10.0 million for expenses and an asset impairment partially offset by recovery of expenses related to the historical portion of the settlement of a licensing dispute, and accelerated compensation expense related to business acquisitions of $1.5 million for the year ended December 31, 2011. Add back depreciation of purchase accounting property, plant, and equipment revaluations of $10.4 million and accelerated compensation expense related to business acquisitions of $18.9 million for the year ended December 31, 2010. | ||
(6) | Add back business consolidation costs. | ||
(7) | Add back charges related to noncash interest expense as a result of the provision adopted in accordance with the ASC Topic of Debt with Conversion and Other Options of $24.6 million and $38.0 million for the years ended December 31, 2011 and 2010, respectively. Adjust for imputed finance charges of $6.2 million and $1.5 million associated with contingent consideration on business acquisitions for the years ended December 31, 2011 and 2010, respectively. | ||
(8) | Add back loss on early retirement of debt. | ||
(9) | Adjust for gain on divestiture of equity investments. | ||
(10) | Adjust for gain on impaired security recovery of $7.1 million, a discontinuance gain on cash flow hedge of $0.6 million and gain on foreign currency related to joint venture divestiture of $1.0 million offset by loss on discontinuance of cash flow hedge of $12.9 million and joint venture purchase accounting adjustment of $1.2 million for the year ended December 31, 2010. | ||
(11) | Non-GAAP tax differs from GAAP tax expense due to the exclusion of the aforementioned business combination related charges, non cash charges, and one-time costs which are not indicative of the profitability or cash flows of the Company’s ongoing or future operations. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation. | ||
(12) | Add back noncash charges for purchase accounting inventory revaluations and depreciation of purchase accounting property, plant, and equipment revaluations attributable to non-controlling interest, net of tax benefit. | ||
(13) | Eliminate noncash interest charges from diluted earnings per share calculation, as the noncash interest is excluded from the calculation of Non-GAAP net income. | ||
LIFE TECHNOLOGIES CORPORATION | |||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||
For the year | |||||
ended December 31, | |||||
(in thousands)(unaudited) | 2011 | 2010 | |||
Net income | $ 412,119 | $ 377,858 | |||
Add back amortization and | |||||
share-based compensation | 394,326 | 386,621 | |||
Add back depreciation | 123,578 | 122,978 | |||
Balance sheet changes | (82,781) | (101,435) | |||
Other noncash adjustments | (38,107) | (46,933) | |||
Net cash provided by operating activities | 809,135 | 739,089 | |||
Capital expenditures | (99,293) | (124,817) | |||
Free cash flow | 709,842 | 614,272 | |||
Net cash provided by (used in) investing activities | (52,591) | 5,013 | |||
Net cash used in financing activities | (627,268) | (407,808) | |||
Effect of exchange rate changes on cash | (4,790) | 5,505 | |||
Net increase in cash and cash equivalents | $ 25,193 | $ 216,982 | |||
LIFE TECHNOLOGIES CORPORATION | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
December 31, | December 31, | ||||
(in thousands) | 2011 | 2010 | |||
ASSETS | (unaudited) | ||||
Current assets: | |||||
Cash and short-term investments | $ 881,994 | $ 854,801 | |||
Trade accounts receivable, net of allowance for doubtful accounts | 636,998 | 587,456 | |||
Inventories | 377,866 | 323,318 | |||
Prepaid expenses and other current assets | 175,222 | 280,950 | |||
Total current assets | 2,072,080 | 2,046,525 | |||
Long-term assets | 7,094,346 | 7,439,674 | |||
Total assets | $ 9,166,426 | $ 9,486,199 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
Current liabilities: | |||||
Current portion of long-term debt | $ 450,839 | $ 347,749 | |||
Accounts payable, accrued expenses and other current liabilities | 989,645 | 798,636 | |||
Total current liabilities | 1,440,484 | 1,146,385 | |||
Long-term debt | 2,297,653 | 2,727,624 | |||
Other long-term liabilities | 794,778 | 1,174,161 | |||
Equity | 4,633,511 | 4,438,029 | |||
Total liabilities and equity | $ 9,166,426 | $ 9,486,199 | |||
SOURCE Life Technologies Corporation
Related Articles
- Life Technologies Foundation Announces Lead Sponsorship of Smithsonian Exhibit to Celebrate 10th Anniversary of the Human Genome Project's Completion
- Life Technologies to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
- Life Technologies Announces First Quarter 2012 Results
- Ion Proton™ Systems Installed and Operational at the Baylor College of Medicine Human Genome Sequencing Center
- Life Technologies to Build Additional $20 Million State of the Art Cell Culture Facility in Scotland
- Critical Alerts for Hartford Financial, Deere, Blackstone Group, Life Technologies, and ITT by Seven Summits Research
- Life Technologies Sets 1st Quarter 2012 Earnings Release Date for Tuesday, April 24, 2012
- Life Technologies Receives the First and Only PCR-based FDA Method Equivalency for Salmonella Enteritidis in Poultry Eggs and Environmental Samples
- Life Technologies to Accelerate Adoption of Next-Generation Sequencing in HLA Through Key Partnerships
- Life Technologies Announces Expansion of TaqMan® Mutation Detection Assays
Related Partner Headlines
- Life Technologies Corp (LIFE): Today's Featured Health Care Loser - TheStreet.com
- UPDATE: Goldman Sachs Maintains Neutral Rating, Raises PT on Life Technologies - Benzinga
- UPDATE: Citi Upgrades Life Technologies to Buy - Benzinga
- Life Technologies Down 6% As Oxford Nanopore Enters Gene Sequencing Market - Benzinga
- UPDATE: Citigroup Raises Target to $52 on Life Technologies - Benzinga
- UPDATE: Deutsche Bank Raises Target to $49.50 on Life Tech - Benzinga
- Citigroup Maintains Life Technologies at Neutral, Raises PT from $44 to $52 - Benzinga
- Life Technologies Corp Stock Upgraded (LIFE) - TheStreet.com
- Life Rises On Unusually High Volume (LIFE) - TheStreet.com
- Life Rises On Unusually High Volume (LIFE) - TheStreet.com
JIM CRAMER wants to work for YOU. JIM does the research -- YOU get email alerts each time he trades. JIM provides access to his actual portfolio -- YOU can use it to guide your portfolio strategy.
Try Jim's Action Alerts PLUS for FREE!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
